Novartis Ditches Two Products In China To Focus On New Launches
This article was originally published in PharmAsia News
Executive Summary
Amid regulatory approval delays and commercial uncertainties, multinationals are reviewing and adjusting local product strategies to adapt to a new norm. As part of life cycle management, Novartis has just out-licensed two established drugs in line with its intention to focus on innovative products.